Search the Newsreel

Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com

This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due …

Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have filed an amended Schedule 13G/A, reporting a collective beneficial ownership of 7,999,025 Class A ordinary shares, representing a 9.74% stake in MoonLake Immunotherapeutics (MLTX). This ownership includes 1,000,000 Pre-Funded Warrants, …

Q3 EPS Estimate for Kyverna Therapeutics Lifted by Analyst

HC Wainwright has increased its Q3 2026 EPS estimate for Kyverna Therapeutics (NASDAQ:KYTX) to a loss of $0.66 per share, an improvement from its previous forecast of a $0.78 loss. The firm maintained a "Buy" rating and a $25.00 price target for the stock. …

VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M

* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating …

H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35

H.C. Wainwright has reiterated its Buy rating for MiNK Therapeutics (INKT.US), maintaining a price target of $35. This indicates the firm's continued positive outlook on the company's stock performance.

HC Wainwright Has Positive Estimate for MAZE Q3 Earnings

Q3 EPS Estimate for LENZ Therapeutics Increased by Analyst

RTW Investments discloses 9.99% Tenax Therapeutics (TENX) position with 2.87M shares

RTW Investments and Roderick Wong, M.D. have reported a beneficial ownership of 9.99% in Tenax Therapeutics, Inc., amounting to 2,866,654 shares. This stake includes shares issuable upon the exercise of warrants, subject to a 9.99% beneficial ownership limitation. The filing, a SCHEDULE 13G/A, details …

Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol

Galectin Therapeutics reported a Q2 2026 net loss of $9.2 million and held $13.3 million in cash. The company plans to submit a registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis in Q3 2026, having aligned with the FDA on key trial …

Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing

Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly reported a 3.25% ownership stake in Viridian Therapeutics (VRDN). This ownership, totaling 3,592,740 shares, is held with shared voting and dispositive power. The filing is based on 110,427,682 shares …

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) reported a Q3 loss of $0.09 per share, aligning with analyst expectations, but missed revenue estimates significantly with $0.01 million compared to an expected $1.5 million. The company's stock has underperformed the S&P 500 this year, and while the current …

Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants

Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 16,270,187 shares of Tango Therapeutics (TNGX), representing 9.8% of the company's outstanding common stock. This includes 12,277,000 directly held shares and 3,993,187 pre-funded common stock purchase warrants, which are exercisable …

Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake

Sirenia Capital Management LP and Alex Silverstein have reported a 9.5% beneficial ownership stake in Design Therapeutics, Inc. (DSGN), totaling 5,963,936 shares, which includes shares issuable from call options. This disclosure was made in a Schedule 13G filing, indicating a passive investment purpose rather …

Sirenia Capital reveals 1.70M-share DNTH stake in Dianthus Therapeutics (DNTH)

Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 1,696,751 shares in Dianthus Therapeutics Inc. (DNTH), representing 3.1% of the company's outstanding common stock. This figure includes 510,400 shares issuable upon the exercise of call options. The filing indicates shared …

Form 8K Neumora Therapeutics Inc For: 14 August By Investing.com

This article reports on Neumora Therapeutics Inc.'s Form 8K filing for August 14. The filing contains important company information for investors, who should review the full document for complete details. The stock symbol for Neumora Therapeutics Inc. is NMRA, and it experienced a -7.51% …

Balkrishna Paper Mills Q1 Results: Net loss narrows to ₹1.80 crore

RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G

RTW Investments, LP and Roderick Wong, M.D. have reported an 8.3% beneficial ownership stake in Kailera Therapeutics, Inc. (KLRA) through a Schedule 13G filing. This amounts to 10,776,820 shares of common stock, based on 129,565,608 shares outstanding as of May 20, 2026. Both reporting …

Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement

Galectin Therapeutics (GALT) announced a net loss of $9.1 million for Q2 2026, or $0.14 per share, an increase from $7.6 million in the prior-year quarter. The company also reached an agreement with the FDA on key elements for its planned Phase 3 belapectin …

CAPRICOR THERAPEUTICS ($CAPR) Releases Q2 2026 Earnings

Earnings Beat: C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

C4 Therapeutics, Inc. (NASDAQ:CCCC) recently surpassed Q2 revenue expectations by 66% and reported a smaller loss per share than anticipated, leading analysts to upgrade revenue estimates and reduce loss projections for 2026. The company's stock also saw a 15% increase in its price target …

Sei Investments Co. Invests $849,000 in Avalo Therapeutics, Inc. $AVTX

Sei Investments Co. has acquired a new stake in Avalo Therapeutics (NASDAQ:AVTX), purchasing 56,854 shares valued at $849,000, which represents 0.19% of the company. Institutional investors now own 87.06% of AVTX, and analysts maintain a "Moderate Buy" rating with an average price target of …

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Quince Therapeutics announced its second-quarter 2026 financial results, highlighting the acquisition of Orphai Therapeutics and its lead program, LAM-001, which targets serious pulmonary diseases. The company also completed a $115 million private placement financing, bolstering its cash reserves to fund operations through 2028. Clinical …

CAPR Stock Jumps As Lancet Data And Upgrade Shift Odds

Capricor Therapeutics (CAPR) stock surged by 97.39% following the publication of positive Phase 3 HOPE-3 trial data in The Lancet, showing its drug deramiocel slowed upper-limb decline in Duchenne muscular dystrophy. This scientific validation, coupled with an FDA Biologics License Application (BLA) under active …

RTW Investments (SYRE) reports 4.8% Spyre Therapeutics stake for managed funds

RTW Investments, LP and its managing partner, Roderick Wong, M.D., have reported a beneficial ownership of 4,251,996 shares of Spyre Therapeutics (SYRE) common stock, representing 4.8% of the outstanding shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong exercising …

MapLight Therapeutics, Inc. Stock 12‑Month Price Target Cut to $28.77, Implies 148% Upside

The average 12-month price target for MapLight Therapeutics, Inc. (MPLT) stock has been revised down slightly to $28.77 from $29.31, based on estimates from 13 analysts. This new target suggests a significant 148% potential upside from its Aug. 13 closing price. The consensus rating …

Form 8K MapLight Therapeutics Inc For: 13 August By Investing.com

Investing.com reports on a Form 8K filing by MapLight Therapeutics Inc. for August 13th. The article mentions the company's stock symbol MPLT and its daily performance, showing a 1.47% increase.

Fate Therapeutics doses first patient in FT819 lupus trial

Fate Therapeutics has dosed the first patient in its Phase 2 RECLAIM-LN clinical trial for FT819, a treatment for refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The trial aims to enroll approximately 53 patients with Class III or IV lupus nephritis, expecting to …

Driehaus Capital trims percentage stake in Definium Therapeutics (DFTX) to 5.36%

Driehaus Capital Management LLC has reduced its stake in Definium Therapeutics (DFTX) to 5.36% as of June 30, 2026, down from 6.64% reported on December 31, 2025. This ownership represents 6,845,276 shares of common stock, held in various client accounts managed by DCM. The …

Akari Therapeutics reports Q2 results

* Akari Therapeutics press release [https://seekingalpha.com/filing/309948312] (AKTX [https://seekingalpha.com/symbol/AKTX]): Q2 net loss was $4.8 million, compared with $1.9 million for the second quarter of 2025. * Cash totaled $7.7 million as of June 30, 2026, compared with $5.2 million as of December 31, 2025. * …

Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14%

Kymera Therapeutics (NASDAQ: KYMR) stock has experienced an 8-day winning streak, resulting in a 14% increase in its stock price. The article highlights this significant recent performance for the company.

Handelsbanken Fonder AB Buys 86,000 Shares of Nurix Therapeutics, Inc. $NRIX

Handelsbanken Fonder AB increased its stake in Nurix Therapeutics (NASDAQ:NRIX) by 15.7% in the second quarter, acquiring an additional 86,000 shares, bringing its total holdings to 633,000 shares valued at approximately $15.4 million. Despite this institutional buying, insiders sold a significant number of shares, …

Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA

BofA Adjusts Price Target on Candel Therapeutics to $12 From $9

BofA has increased its price target for Candel Therapeutics (CADL) to $12, up from the previous $9. This adjustment follows several recent announcements from Candel Therapeutics, including its Q2 earnings results, the initiation of a global Phase 3 trial for a lung-cancer drug, and …

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics reported its third-quarter fiscal year 2026 financial results, highlighting the FDA approval of LYTENAVA™ for wet age-related macular degeneration (wet AMD). The company is preparing for a U.S. commercial launch by the end of 2026, with an estimated potential to exceed $500 …

FDA-approved LYTENAVA targets wet AMD; U.S. launch planned by year-end 2026

Outlook Therapeutics (OTLK) reported a Q3 fiscal 2026 net loss of $20.3 million but highlighted the FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet age-related macular degeneration, the only FDA-approved ophthalmic bevacizumab for this condition. The company is preparing for a U.S. launch by year-end …